Know Cancer

or
forgot password

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41


Phase 3
18 Years
N/A
Open (Enrolling)
Male
Metastatic Prostate Cancer

Thank you

Trial Information

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41


OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter, 2 arm study.

The study population will consist of prostate cancer patients with metastatic bone disease
for whom androgen-deprivation therapy is planned. After stratification based on the
patient's age, performance status, and severity of metastatic disease, the patients will be
randomized at a 1:1 ratio to the following treatment arms:

- Daily oral risedronate combined with androgen deprivation

- Daily oral placebo combined with androgen deprivation

Initial clinical evaluation will be performed during the 2-week screening period. While
patients receive per-protocol treatment, study assessments will be performed every 4 weeks
during the first 3 months, and every 12 weeks thereafter.

Performance Status: ECOG 0 to 2

Life Expectancy: At least 12 weeks

Hematopoietic:

- ANC > 1,000/mm3

- Platelet count > 100,000/mm3

- INR < 1.5 x upper limit of normal unless on therapeutic anticoagulation

- Partial thromboplastin time (PTT) < 1.5 x upper limit of normal unless on therapeutic
anticoagulation

Hepatic:

- Bilirubin < 1.5 mg/dL

- Alanine transaminase (ALT) < 2.5 x upper limit of normal

Renal:

- Creatinine clearance of > 30 mL/min (by Cockcroft-Gault)

Cardiovascular:

- No significant history of uncontrolled cardiac disease (i.e., uncontrolled
hypertension, unstable angina, and congestive heart failure).

Pulmonary:

- Not specified

Calcium:

- Corrected serum calcium = (4.0 g/dL - actual albumin g/dL)x 0.8 + serum calcium


Inclusion Criteria:



- Histologically or cytologically confirmed adenocarcinoma of the prostate with
metastatic bone disease (by CT, MRI or bone scan) with plans to start or be < 30 days
from beginning androgen deprivation therapy. Patients with lymph node or visceral
metastases only are not eligible

- Patients may receive palliative radiation therapy at the investigators discretion
during the first 4 weeks of beginning protocol therapy.

Exclusion Criteria:

- No neuroendocrine, small cell or transitional cell cancer of the prostate No abnormal
bone metabolism (i.e., Paget's disease, untreated hyperthyroidism, untreated
hyperprolactinemia, untreated Cushing's disease).

- No use of calcitonin within 14 days before being registered for protocol therapy or
any previous use of bisphosphonates.

- No major surgery within 4 weeks of registration to protocol therapy.

- No adjuvant chemotherapy within 6 months of registration to protocol therapy.

- No previous chemotherapy for metastatic disease.

- No hormonal therapy in the adjuvant setting within 12 months of registration to
protocol therapy; previous hormonal therapy must not have exceeded 6 months.

- No prior history of malignancy in the past 5 years with the exception of basal cell
and squamous cell carcinoma of the skin.

- No history of allergy or drug reactions to bisphosphonates.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Outcome Measure:

To evaluate the ability of risedronate to prevent skeletal complications

Outcome Time Frame:

36 months

Safety Issue:

No

Principal Investigator

Christopher Sweeney, M.B.B.S.

Investigator Role:

Study Chair

Investigator Affiliation:

Hoosier Oncology Group, LLC

Authority:

United States: Food and Drug Administration

Study ID:

HOG GU02-41

NCT ID:

NCT00216060

Start Date:

October 2003

Completion Date:

March 2008

Related Keywords:

  • Metastatic Prostate Cancer
  • Prostatic Neoplasms

Name

Location

Cleveland Clinic Foundation Cleveland, Ohio  44195
Indiana University Cancer Center Indianapolis, Indiana  46202-5265
Cancer Institute of New Jersey New Brunswick, New Jersey  08901
Gundersen Lutheran Medical Center La Crosse, Wisconsin  54601
Peoria Urological Associates Peoria, Illinois  61614
San Bernadino Urological Associates San Bernadino, California  92404
Siteman Cancer Center Saint Louis, Missouri  63110
Center for Cancer Care at Goshen Health System Goshen, Indiana  46526
Urology of Indiana, LLC Indianapolis, Indiana  46202
Center for Urological Research La Mesa, California  91942
Drs. Werner, Murdock and Francis PA Urology Associates Greenbelt, Maryland  20770
Kansas City Urology Care Kansas City, Missouri  64131
AccuMed Research Associates Garden City, New York  11530
Oregon Urology Specialists Eugene, Oregon  97401
Urological Associates Of Lancaster Lancaster, Pennsylvania  17604-3200
Salt Lake Research Salt Lake City, Utah  84124
Lawrenceville Urology Lawrenceville, New Jersey  08648
Northern Indiana Cancer Research Consortium South Bend, Indiana  
Triangle Urological Group Pittsburgh, Pennsylvania  15212
Mayo Clinic Rochester Rochester, Minnesota  55905
Medical & Surgical Specialists, LLC Galesburg, Illinois  61401
Oncology Hematology Associates of SW Indiana Evansville, Indiana  47714
Quality Cancer Center (MCGOP) Indianapolis, Indiana  46202
Grove Hill Medical Center Urology New Britain, Connecticut  06052
Innovative Surgical Resources Tampa, Florida  33607
Urology Associates Muncie, Indiana  47303
Urologic Surgery Associates Baltimore, Maryland  21201
Nevada Urology Reno, Nevada  89511
Staten Island Urological Research, P.C. Staten Island, New York  10304
David Reed, M.D. Seattle, Washington  98166
Madigan Army Medical Center Urology Service Tacoma, Washington  98431